Teva schedules R&D Day for November 11 in New York City

what happened

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) said on October 12 that it will hold an R&D Day in New York on Wednesday, November 11, 2026. GlobeNewswire reported that company executives are expected to outline the development portfolio, opportunities to create value during the coming five years and Teva’s shift toward an innovative biopharmaceutical model under its Pivot to Growth strategy.

The presentations are scheduled to run from 8:30 a.m. to 12:30 p.m. Eastern Time. Attendance at the venue will be limited to invited guests, while analysts and institutional investors who are invited will receive separate registration details. Teva said the webcast and presentation documents will be posted on its Investor Relations website, with a recording expected within 24 hours after the live session ends.

The company also noted that its release may include forward-looking statements reflecting management’s current expectations. Teva listed competition, execution of Pivot to Growth, expansion of innovative and biosimilar medicines, debt, regulatory and litigation matters, and broader financial and economic risks among the factors that could affect results. The notice referred readers to the second-quarter 2026 Form 10-Q and the Form 10-K for the year ended December 31, 2025.

why it matters

The event is set to give investors a closer look at Teva’s development plans and potential sources of value over the medium term. Market attention may also focus on execution risks and the company’s transformation.

instruments